- Home
- PED vs BTAI Comparison
PED vs BTAI Comparison
Compare PED & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PED | BTAI |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 35.6M |
| IPO Year | 2012 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PED | BTAI |
|---|---|---|
| Price | $0.79 | $1.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.50 | ★ $25.33 |
| AVG Volume (30 Days) | 623.2K | ★ 1.1M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,553,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $305.89 | $261.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 28.49 | N/A |
| 52 Week Low | $0.43 | $1.17 |
| 52 Week High | $0.85 | $8.08 |
Technical Indicators
Market Signals| Indicator | PED | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 64.76 | 46.64 |
| Support Level | $0.54 | $1.50 |
| Resistance Level | $0.82 | $2.18 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 84.98 | 31.58 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.